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I NTf~OOUCT I ON 
The environment of the active ingredient in a parenteral 
drug formulation is carE:fully controlled. By a rnanufoctur<3r's 
judiclou~' use of antioxidants, stabilizert;, buffers, c-1nd pre-
expected for the active ingredient. 
When this sume dr·ug formulation is diluted in o larqe 
volume ot intravenous infusion solution, ·t-he controlled 
environmerd· is losi·, and the duration of stabi! li-y of tho 
activo ingredient can be altered markedly. The presence cf 
other drug fornH.iia'fions in admixture co;..~ic fur·ther· cornpllca-re 
s t a b i I 1 ·;- y . Chern i c a ! i n t e r a c t i o n s b 8 t'/;' c fHi t h e m u ! t i p I e c CJ m ... 
ponents cf this mixture could result in a parti~! or co~p!ete 
fn~ctlvltation of the active drug entity. 
intravenous adrni>:-t"ur·es consisting of 01~e or more drug 
f c :- rn u ~ a t i o n s 
1 
d l I u t e C: i n a l a r· g e v o I u rr. e o ·f . i n t r- a v e r1 ~) u s :::. o l u -· 
"tl·:>n, ar·e us8d extensively in curren-t medical or3c"tice. 
De v €~ l o p lHJ n t o ·f !"' e l i a b I e met h o d s to p r e d i cl· ·f· h E:> c S> m p a t i b l l i T y 
s e i r3 c -r i o n • 
have used a visible change as i·he criterlor1 for judging com-





t h e u s e o 'f s p 0 c t r o p hot me t r i c a n a I y s i s + o d e t e c t i' tH?. 0 c c 1HT o n c '<1 
of chemical interactions between two components of an intra-
venous admixture. 
~Ayers (I)~ in a paper revie\~ing the problems confronting 
the physician and pharmacist in handling parenteral admixture,. 
emphasized the need for a comprehensive study of incompatl-
bi i i"i"ies. He stated: 
;----------------------
It is generally acknowledged "!-hat formulations 
6f mnnufactured products are complex and their 
compatibi I ity characteristics are not' the sarne as 
those of the active components alono. P~-odicl-ior:s 
as to how these components w iII r-eact wher1 used a~; 
a combined form, have many times been deficient in 
I ·i g h t o f a c t u a I t r i a I • A n y c h a n g e s i n p 1-1 , p a r -r l c ! e 
size, I ight exposure, solvents, oxidation - reduction 
conditions, can easily upset ·-1-he drug sys-rem, causing 
I oss of aci· i vi ty, i ner·tness cr -t-oxicity. 
Surveys concerning the extant of multicomponeni· admixtures 
prescribed and administered In var·io~s American hospitals havo 
supported Myers's concern. 
Meisler and Skolaut (2) reported that over 50% o'f the 
intravenous solutions administered at the Clinical Center of 
t·he National institute of Health at Bethesda, ~P,ar·yland, con-
·r·ained additives. Of thoir admixtures, 42% contained one or· 
more dr·ugs. Francke (3) reported that, ln a 14 day period at 
i·he University of Illinois Hospital, over 60% of the I.V. 
solutions contained additives. A considerably higher percent-
age was reported by Patterson and Nordstrom (~). Their one 
month survey at the Veterans' Administration Hospital in 
Loulsvi! lc, Kentucky, indicated that 86% of the I.V. solutions 
.. 
""-
contained one or more additives. Holysho and Ravin (5) 
reported that an average of 2.1 additives were mixed in each 
I.V. so!ut"lon dispensed from the centralized I.V. additive 
service at St. Joseph's Hospital in Ann Arbor, Michigan. 
-~ 
.J 
To emphasize the enormity of possible admixture comblna-
tion, Plein (6) stated that, for 500 given drugs, !24)755 
different mixtures of two drugs are possible. If these cln1gs 
are mixed in combinations of more than two, then the number 
----
of pos sib i 1 it i e s becomes-as i" ro-non1Tca1--:- - Cl5r1s raer-in~r -;-rm -rn:rm·b-o-r-- -
of rnulticornponent admixtures administered yeat·ly, the pcter:ilai 
for the occurrence of incompai-ibi I ity must t>e recognized. 
S i n c e I 9 55 , n u me r o u s i nco rn p at i b i I i t y stud I e s h ,:; v e be f.O; n 
reported. In some of the studies, the authors have dealt \\'i"'i-11 
s p e c i f l c a rea s s u c h a s p H a n d s t a b i I i r y p ,-o b I em s o f d r u g a d d i -
tivas. C1·her authors have attempted to determine the compati-
b i I i t v ·:J "f a s p e c i f i c d r u g o r co rn !.J i n a t i o n o f d r· u g s i n s '3 I 8 c tE: d 
I.V. fluids. Stili others have attempted 1o !ncor-pCJrats 
information obtained from various articles into a slngla guide. 
It is interesting to note that the methodology of s·~udy. 
b r- a n d a n d co n c e n t r a t i o n o f t h e d r u g a d d i t i v e s , a ~~ d e s p e c i a : I y 
t h e c r· i -!" e r i a f o r d e t e r· m i n i n g i n com p a t i b i I i t y h a v e b e e n v a r i e ci , 
As a r·esu!t, there have been conflicting reports as ·t-o the 
cornpatibi I ity of certain admixtures. 
The in it i a I ~;tud i es uti I i zed observab I e vi sua I chan~jes 
In the admixture for incompatibi I ity determination; such as 
precipitation, evolution of a gas, color change, or· haze.· 
La·t·er studies have demonstrat-ed tha't ·rhe chemical intere.c~·ior, 
4 
which can affect the nffectlveness of one or more of the 
admixture components need not be manifest by a visual change. 
Changes in pH, oxygen concentration, drug Ddditlve concentra~ 
tlon, I ight exposure, and storage temperature can induce 
chemical interactions resulting in a decreased stability of 
one or more admixture components. It has been suggested ihat j 
the lack of visible changes after a chemical 
! 
interaction mlgh1 
' be attributed to the sol ubi I lty of the end product of the !
reaction (6). 
0 n e o f the f i r s t com p at i b i I i t y c t1 a r t s p u b I i s hod vi a ~; 
p r- o p a·r- e d by Bog ash ( 7 ) i n I 9 5 ~3 • Ad m i x t u res con:-: i s -t- i n q of 'h-1 '' 
p a r- e n l' e r 21 1 d r u ~J f o r· m u I a 'I' I o n s v; E-) r s p r e ~· a r e d a n d o b s E: r v e d f o r 
the appe;:.:rClnce of pa>ticu!at<."'.J rno"t-"t-er immediately <:1f'ter admix··· 
tu('e and ag<:Jin c~ft8r four h()Ut .. ~ .. The cri'i'er·ion for incompati-
l6te matter within a four hour period. 
K i r k I a n d a n d co - w o r- k e r· s ( .S ) co n d u G t e d a n i n co m p a t i b i I i t y 
study Li·y adding 137 pat-ente;al drugs, eitlt~:<r as single or 
Maintaining both drug ~ddltlve concentration and the order 
at mfxlng constant, admixtur·es were prepared and observed 
for· visible chanJGS a-:- defir:.ii'e t!rno interval:.; of l, 6, e1nd 
24 hour-s. 
Admixtures which were clear after 24 hours were classi-
tied as compatible. Admixtures irt l•ihich a naze or prec:lc,itatE', 
·-·-------·--··-·--·---...,~--------.:----
a -Abbott L~boratorles, North Chicago. I I I ino1s. 
b I I it·>' study. 
injec+ion. 
fled ~s !ncompatlble. 
" .J
a "I~"(;· A c: {) rn p l) n ~::;; r1 -:- s y s i s rn i . l\ f ·i4 e r r .s cor!~= -~- i ~r u i· i c; n , \'J h c~ n n t~ c c:.::: s d r· v ; 
nnci the pH v:c)S r·ocordnd. 
solution from a different drug was then added. 
Admixtures conta!nins particulate 
"" 
6 
admixtures was determfned. The author noted that the pH of 
the Incompa-t-ible admixtur(:) roughly parall~./ied the average pH 
of the two combining drugs. 
P a t e I a n d Ph i I I i p s ( I I ) t a b u I ate d a two-corn pone n i· 
i nco m p a 1- i b i I i t y chart for p a renter a I drugs based on a s t i I I 
different method of study. Pre I imir1ar·y work was done by 
mixing a drop of each of the two different solutions of the 
drug additives on a slide, and examining the ml><tur·e under 
a microscope. 
di ILitions of the drugs were prepared and observed. Finally .• 
two component admixtures of ·unstated concentr5·tion were pre-
pared and observed for particulate matter for a 24 hour period. 
The results of their work were presented as an incomp~tibi I lty ~ 
char·t. 
Studies demons-t-r·oting the, occurrence of a chemical inter-
a· c t i o n bet w e e n o n e o r m o r e com p o n e n t s o f a n I . V . a d m i >d u r e 
have been reported. Although visible changes did not occur in 
the admixtures studied, the extent of chemical degradation 
detected in the components was sufficie~t to classify the 
admixtures as incompatible. 
Don y ·· C rot-rea u x ( I 2 ) rep o r ·;- e d t h a i" tetra c y c I i n e , o >: y t e t racy ·· -
G 
clina, and chlortei-r-acyc!ine were found to lose biolog,icC'II 
potency in the presence of vitamin B complex. Riboflavin was 
identified as the cause ot the inactivation of the antibiotics 
through a photo-oxidation process. It was also noted that 
fluorescein, eosin, and methylene blue can cause oxidative 
degradation of the tetracyclines. An important factor 
7 
demonstrated in this early study was the absence of visual 
change in the solutions, even though tetrac:yclino dogr-adaiion 
was sufficient to classify the admixture as incompatible. 
Aft8r a survey of the avai lc1ble data fr·orn chemical 
incompatibility studies, Carlin and Perkin£; (!3) presented a 
method for estimating the reaction rates of different drug 
additives. This method involved calculating the time required 
for a !0% reduction in -t-he potency.of the drug additive at 
------
varJous pH ranges. The authors suggested that the same drug, 
as an adrn i xtu re component in the same pH r·ange, wou I d r8act 
in a similar· manner. Carl in and Perkins stated that this 
method could be used as a guide to predict potentia! admixture 
i nco m pa-t i b i I i t i e s f o ,- the d r· u g s tested , e • g • , t h '" pen i c i I I i n s , 
tetracyclines, 8-compiex vit?:trnin~::;. hydrocor·tisone, and 
aminophylline. 
Two factors relative to drug reactlvity were emphasized 
In this study: a) The acidic or basic character of a drug 
can definitely Influence .Its reactivity, and b) The majority 
of reactions take place by an apparent first order process, 
so that the time required for a given fraction ot a drug to 
react is independent of the or i gina I drug concentration. 
In a detailed study involving admixtures of spr~clfied 
formulations of penici II in$ and tetracyclines in 5% Dextr·ose 
injection, lm·and Latiolais (14) reported an inactivation o1· 
pot ass i u m p e' n i c i I I i n G by t e 1- racy c I i n e h y 9 roc h I o r i d e . The 
d e g r a d a t i o n o f t h e p e n i c i i I i n v1 a s t h f:: r e s u I t o ·f i i' s i n s t a b i I i t y 
ln an acid medium. The acidic pH of ihe admixture was 
attr·ibuted to the tetracycline hydrochlor·ide and to u greater· 
extent to the ascorbic acid present In the formulation. The 
method used to detect drug degradation was based on a spec-
trophotomatrlc assay of the individual drug components. After 
t h e deter m i nat i on o f the w a v e I e n g t h of max i mum a b so r p l i on ' i· he 
absorbance of each drug was determined before and after admix-
ture. Tho decrease in absorbance of ·rhe pen i c iII in cornponc'nt 
reflected a 69% loss of activity within a four hour period. 
Stabi i i~ty_2._tudies for Parenteral Drugs 
The s t a b i I i i"y o f a p h a r m a c e u t i c a : d r- u ~~ has been de f 1 ned "\ 
' 1 
as thE.l period of time from completion of the preparution unt!! J 
I 
it no longer· fulfills the specifications given in the compen- l/ 
\,,, 
From this statement, it is evident that knowledge . 
.•. . ~,,.,~·"'" 
dia, or unti I tile potency reduced by not more than has been 
10% (i5). 
of th<> 'factors which Influence drug stabi I ity is of thG uin·:oc;t 
importance if they ar·e to be used proporly. To use a drug 
bf~yond its stabi I ity period is dangerous, as its thet~apeuii:~ 
. , 
effectiveness wi I l have diminished and the expected pat!ent 
response may not be evidenced. Also the decomposition of some 
drug formulations result~ in the formulation ot chemical 
by-products which may cause untoward or toxic mQn!festai·ions 
in the patient. 
Whittet (16) reported several facto~s which produce a 
chemical degradation without altering the physical appearance 
of a drug formulation. Changes in pH, oxygen concentration, 
! igh-t" cxposur·e, storage +emperai-LH'B are in·.::luded in the 







Lin and Lackman (!7) have presented examples of the 
effect O)< photo-chemical degradation in parenteral drug formu-· 
.lations and their influence on stability. Oxygen in the 
presence of sun I ight produce loss of stabi I ity in solutions 
of sulfonamides, reserpine, and sympathomimetic amines such 
as epinephrine. 
Several stabi I ity studies for parenteral drug formula-
tions have been conducted, and ln general, have concentrated 
in thr·ee dreas: 
( I ) Stabi I ity of a drug after reconstitution. 
( 2) Stability of a drug a·fi·er dilution in a 
large volume of intravenous infusion solu-
tion. (single component admixture) 
(3) .Stabi I ity of a dru~:; after· dilution in a 
large volume of intravenous solution in ths 
presence of one or more other drug additive~. 
(multiple component admixtures) 
La t i o i a i s a n d co - w o r k e r· s ( I 8 ) h a v e corn p i I e d a t a b u I a "i' i o n 
of over 300 drug products which r~quire reconstitution prior 
to administration. The tabulation tontains the recommended 
di luent 1 the quantity to be used and the resultant concentra-
t i o n cH· t h e d r u g i n s o I u t i o n . T h e s t a b I I i t ''/ o f t h e d r ·u g a f t e r· 
di lu·ricn wl"''h the di luen-r when kept under specified conditions 
of storage is also given. One factor, readily apparent from 
this study, was that different brands of tho same drug entity 
may have different durations of stabl I ity. The manufacturer's 





product pH can alter the stabi I i-1-y of parenteral drug 
formulations. 
Many parenteral products have spec~fic reconstitution 
procedures which must be followed to assure their s"tabi I ity. 
Shoup ( 19) has given examples of parenteral dr·ug formulations 
in which stabi I ity can be altered if one or more of several 
factors are not contra I I ed. These factors inc I ude the 
diluent used .• its temperature and pH, the presence of bac-
He also reported that stabi I ity after reconstitution of 
certain antibiotics could be prolonged by storage in tha 
frozen state. After reconstitution, potassium penlci I I in G 
is stable for only seven days under refrigeration. However, 
when kept ·frozen below -l8°,'in a concentration of one mi II ion 
~-
units per· mi., the stability ls increased to at least 12 \\1eeks. 
R~constituted cephalothin sodium Is stable for 48 hours under 
refrigeration. Storage at -20~ at a concentration of 230 mg./ 
mi. wi II increase stabi llty to six weeks. 
Bair and Carew (20) investigated the stability of anti-
biot-ics after single component admixtttre. Ten ~ntibioi"ics 
~ 
in their usual therapeutic concentrat·ions, were diluted in 
four different parenteral solutions. The 24 hour stabi I ity 
of thesG admixtures was te~ted by physical and microbiological 
assay. I~ was reported that six of the antibiotic admixtures 
were stable, i.e., less than 10% loss of the initial potency, 
in all 'four of the I.·V. infusion solutions. Certain admixtures 
containing erythromycin, nafci I I in sodium, novobiocin sodlum, 
I i 
oxoci II in sodium and o><yte-f'racycl ine hydrochloride were bund 
to have lost greater than !0% of their ini-tial potency over· u 
24 hour period and were classified as subpotent. Because they 
demonstrated that the stabi I ity of certain antibiotics after 
admixture could be reduced markedly, it is suggesl·ed that ai I 
' 
antibiotic admixtures be administered as soon as possible after 
admixture. 
Galle! I l (21) conducted studies on the stabi lit·)" and 
-~----
dUra t i 0 n o 'f act i Vi tyof sf X d-rugs o'T dTf-;f e (erltc--phi'JF!11a ctnlTg_i_c_a-{-- ---
categor·ies a~ter reconstitution and dilution in I.V. infusion 
so I u -r i on s . The clr .. u g s i n c I u de d we r c pre d n i so I one sod i urn s u c c i -
nate, mercaptopurine sodium, cyclophosphamide, math lei I I in 
sodium, ampicillin sodium, and amphotericin-B. The study was 
I lmitod to sihgle component admixtures of the drug at thera-
peutic conc~n"l"t-ation a·fter dilution in both Sodium Chloride 
l·r,jection und .5% Dextrose Injection. Sample solutions v1er·e 
inspec-t-ed visually for particulate matter, assayed eithE:)i 
spectrophotometrica!iy or- microbiologically, and the pH 
recorded over a period of one to four weeks. ·During this 
per-iod, the duplicate adrnlxtur·es Vlt3re stored at 25° (room 
temperature) and e1t 5° (refrigeration). The results wer-e 
then compared to official statements concerning the administra-
tion and stablllt·y of the drugs in I.V. solutions. It was 
s h o w r; t h a 't t h e s t a b l I i -t· y o t d r u g s i n u s i n g I e co rn p o n e n t a d rn l x ~-
ture could be quite differer·t from the stabl I ity of reconstl-
1·uted solutions reported in the official statements and in 
pharmaceutical manufacture's brochures. He suggested that 
drug stab! I ity after dilution was a -function of the change 
In concentration, change in pH, storage temperaturej and 
I ight exposure. 
i2 
In a continuation of his earlier work, Gal lei I i and 
co-workers (22) eva I uated the stab iIi ty of 1.6 par·entera I 
formulations o-f antibiotics. The specific purpose of the 
study was to determine the duration that the selected anti-
biotics would retain their antimicrobial potency after single 
---------com p o n e nt-cramix-t-ure-s--;--Th-e--dr u -g-s- -o s e-d- 1-rr--t h-e- si'-u d y --we r e---------~ 
admixed at ,therapeutic concentr·ation in both Sodium Chloride 
Injection and 5% Dextrose Injection. Each of the sample 
solui·ions was inspected visually 'for physical compatibility, 
the pH recorded, and assayed micr-obiologically. This was 
done cH spec if i ~'d i nterva Is up to two months. The admixtures 
were stored in darkness at constant temperatures of 25° and 
5o. 
All antibiotics testeds except ampicillin sodium, r-etained 
their initial antimicrobial potency for a minimum of one month 
at 5° ln both Sod I u m C h I or i de I n j e c t i on a n d 5% Dextrose I n j e c-
tion. The antimicrobial activity of five antibiotics (ampi-
cillin sodium, penicillin G potassium, buffered, cephalothin 
sodium, nafcillin sodium, and tetr-acycline hydrochloride) a't 
25° varied considerably depending upon which vehicle was used. 
Three conclusions ware reached, based on the experience 
of this study: 
( I ) Th~ storage temperature after admixture can 
have a marked influence on the duration of 
!3 
stabi I ity of the antibiotic; storago under 
ref! ... igeration (5°) is preferred to room 
temperature storage (25°). 
( 2 ) Ph y s i c a I c h a n g e s ( co I o r c h a ng e s ) w h i c h may 
occur were .not an index of drug stab iIi "ry. 
A I I of the adm i xi"ures ~vh i ch exhibited such\ 
changes retained their initial potency. 
(3) With the exception qf a change of pH of 
three units in methci II in sodium, it 1:1as 
impossible to correlate minor changes tn 
pH with decrease in drug activity. 
Parker's (23) interlrn r·eport on the stabilii·y o·f eight 
p a r e n t e r a I d r· u g f o r m u I a t i o n s , a f t e r s i n g I e co r11 p o n e n t a d m i x ·-· 
tul-es in various I.V. solutions, utilized both chemical and 
biological assays. The stabi I ity of each drug (90:t of "the 
initial concentration remaining) was deterniined for intervals 
up to 72 hours. Again, the pH of each admixture was noted. 
Although several admixtures exhibited a significant decorn-
position of the active ingredient with the ex~eption of one, 
alI were free of any visible change during the duration of 
-
the study. Once again, the admixture pH, drug concentration, 
-
and br-and variation in formulation appeac .. ed to.be dominant 
f ·acto r s i n t he de g r a d a -1' I o n o b s e r v 8 d . 
I n a co n t I n u a t I o n o ~: h I s e a r I i e r w o r k : P a r k e r· ( 2 4 , 2 .5 , 
26, 27) presented a series of detailed stabi llty studies for 
seven pa1~snteral drug for·mulations, both .in single and double 
component admixtures. Single component admixtures at 
therapeutic concentrations were adjusted to varying 
by the addition of acid or base. Using either spec-trophoto-
metric or microbiological assay, the 24 hour stabi I ity of the 
drug admixture at different pH values was obtained. The 
results of this study were then compared to stabi I lty data 
obtained for the same drug after admixture in various I .V. 
solutions. 
To obtain further data, t~o ot the parenteral drugs 
------
tested were admixed, individually, with other drug additives 
to form double components: The stabl I ity data obtained from 
this study were also compared to the previous tests. This 
study demonstrated a striking correlation between the final 
pH of the admixture and the duration of stabi I ity. 
Dancey and Carew (28) investigated the therapeutic avail-· 
ability of various concentrations of antibiotics along with 
other intravenous additives after admixture in various I .V. 
solutions. Each of the 68 multicomponent admixtures were 
assayed··microbiologically four times over a 24 hour period. 
In addition, the pH was record~d before each assay and visual 
examinations of the admixtures were macte. With the exception 










' admixtures investigated were found to maintain their antibiotic 1 
I P \, 
a.uthors f H , 
i •· ~ } 
between f tfo\\! 
potency for a 24 hour period after preparation. 
also stated that there appeared to be no corr·e!ation 
a loss of activity and a change in admixture pH.) 
the authors of it Is interesting to note that three 
I ~~(\ ~(~ I 
different stabi I ity studies (22, 23, 28) have made somewhat 
d I f 'f e ·r e n t r· ern a r k s co n c e r n i n g -r he e f f e c t of pH a n d the 
::;tabilii·y of the drugs tested. Potassium penicillin GJ in 
a concen-tration of 1··2 mi II ion units/1 iter, was used in a I I J, s. \ 
three studies. Both Ga I I e I I i and Dancey reported 
,,j~~ 
a pH change I ~p~ 
I l 
l'n -,c+'iv'+y! I 0 ... . ' I • t in admixture and storage but observed no decrease 
However, Parker reported that the activity of the drug was pH 
dependt'>nt. 
An explanation to this apparent discrepancy ! ies with 
When the admixtures pH changes fal I within this range, os in 
the first ·lwo instances, no loss of ac-t·ivity was observed. 
When the range is exceeded, as in Parker's study, the activity 
of the drug wi I I be pH dependent .. 
As a I ready indicated, the pH of an adm! xtu re may have a 
profound influence on -t-h~~ sol ubi I i·ty and chemir:;al stabi I ity 
of the drug components. An alteration in pH is probably the 
chief cause·of incompatibility in I.V. admixtures (29). A 
numbr::r of other inves-t-igators have expressed s i m liar v! ews 
and have presented several studies to demonstrate the relation-
ship betwGon pH and incompatibility. 
ro explore the apparent relationship of pH to in~ompati-
bility, vl<;bb (30) rearranged in1 I.V. compa·ilbl!i-t-y chart 
com p i I e d b 'y' P cd· E:1 ! a n d P h i I I i p s ( ! I ) ~:; u t h (} ·i· t h (-3 o r g a n i c ~; a I t s 
(I.V. adcillvo:.:,) were lis-t-ed in terms of increa::;ing pH, (}nd 
we(e a·r right ·angles to the same sa11·s I isi·ed ln terms of 
decrL:;a~;ing pH. A pattern of incompariblo adn1ixtur-es '.-I<:J7. ~ho\•ln 
16 
to cluster mainly in the upper left and lov.'er' right portions 
of the chart. These results indicated that, generc.=1ily, solu-· 
tions of high pH are mutually incompatible with solutions of 
low pH. 
E d \I/ a r d ( 3 l ) co n d u c t e d a n i n v e s t i g a t i o n to d e t e r m i n e t h e 
pH change In an intravenous vehicle when a drug, or combina-
tion of drugs at definite concentrations were added. This 
information was then compared to the published pH r~nge of 
parison were used subsequently to predict the possible acid-
base stabl i ity of a drug or drug combination in a vehicle. 
t\drnixtures Y.Jere class_ified as incompai"ible v;hen the pH of 
the so! u-ti on was outside the accepted stab iIi ty range of one 
or more of the drug components. 
Many factors relative to the pH of admixtures were 
apparent from this study: 
(I) The order of mixing may influence final 
pH due to .a possible buffering action of 
the drug additives. 
(2) Increasing the concentration of the drug 
additive may produce only minor changes 
in pH. 
(3) The wide official pH range of the I.V. 
infusion solutions may affect final pH. 
(4) The change In pH, per quantity of drug 
added to a given volume of solution, 
varied I ltt!e from one unbuffered vehicle 
to the other. 
17 
The effect of pH on the sol ubi I ity of ampici II in sodium 
'II a s r· e p o t t e d by ~1 i y a k e a n d Key o f u z i ( 3 2 ) • So I u t i o n s o f amp ! -
cillin sodium in distilled water at concentrations of 250 mg./ 
m I • a n d 50 m g • I m I . we r e p rep are d a n d the pH r e co r d e d . The pH 
range for these solutions .was 8.4- 8.8. By reduction of the 
solution pH with the addition of an acid, the authors deier-
mined Jhe pH (4.2) at which separation of the free ampici II in 
acid occurred. This separation of the ampici I I in was manifest 
p o n e n t ad rn i x t u r e s o f t h e two co n c e n t r· a t i o n s o f amp i c i I I i n 
sodium were then prepared with 120 different parenteral drug 
formulations. Cloudiness occurred In 26 admixtures wit~ a 
pH range of 4.2 or below. However, the authors reported that 
"i" h f:J s e p a r a t i o n o f a rn p i c i I I i n co u I d b e p r e v e n t e d by t h e u s e o f 
a bu"ff8r- sys-J-orn which wouid r·Gtard pH change. 
Bufft=.:Jr cZJpacity is defined as the ability of a system to 
resist a change in pH by the addition of an acid or base. 
Parker (33) suggested that the buffer capacity of either inira-
venous solutions or drug additives may greatly influence the 
admixture pH. In general, intravenous solutions containing 
organic anions such as lactates and acetates present In 
f<ingers Injection, U.S.P., and Lactated Ringers Injection, (~~~g,n 
U.S.P., have a relatively high buffer capacity. lntr·avenous ~-~ 
solutions containing electrolytes and monosaccharides such as, J 







Sodium Chloride Injection, U.S.P., Dextrose Injection, 
tive drug may precipitate from an intravenous solution 
18 
containing organic anions at pH of 5.5, and not from a dextrose 
solution having a pH of 4.5. In the latter case, the acid sensi-
tlve drug may have enough alkalinity to raise the pH of the 
'· 
admixture beyond that of precipitation. 
;=-
In sp~te.ot the contributions made by those investigators, 
whose work has been reviewed here, one might be curious to find 
other instances of incompatibi I ity which may not be made appar-
ent by development of a precipitate or other visual signs of 
combination with pressor agents tor the treatment of cardia-
genic shock, this study wi I I examine the possible interactions 
of one such pressor amine, mei·araminol bitartrate, with a group 
of corticosteroid preparations. The admixtures wi I I be examined 
spectrophotometr i ca I I y to assess the adv i sab iIi ty of these corn-
binat1ons. 
EXPERIMENTAL 
The purposo oi' the experimental work was to demon.s-t··ate. 
the us9 of dlfferentlel spe~trophotometric anaiysis in detect-
l nrJ occurrence of chemical interactions between 
pononts of an lntraven~us admixture. 
T h e a d m i >: t u r '=' s u s o d i n t h i ·::; s t u d y w e r· e p r· e p a r e d i n b o t h 
Scdium Chicridc injt.'crion, U.S.I"., and SJ!. Dextrose ;njoction, 
n1so!t;)tlE.~ SC•dium [)hosphai"o (Hydeii"r·asoiEl), (18><amethasone sociiU:li 
phosph~te (0ecadron 3 ) methy!prsdnfsolone sodium succinate 
( S o I ~~ f·l! e d r c I b ) , h y d r o co r· t i s o n ~~ ( r .... c--+<>fb' ....... } i ' ,, ) ' hydrocortlsone-21-
phosphate (Hydrocortonea), anj hydrocortisone soalum succin~te 
. I<":,....,! iJ r'n 1"·1· r ..d· b) \ ~\.,; • v .. .... . 'f 
The purpo·,_,:e of the preli:n:nc:r"y invsstigc-1t·:on was 1·o 
D <:: >ci-r o s e I n j o c t ! o n • T h P r-<'l :-3 u ! t a n i' s p e c t ~- a w e r .s co n .s i d 8 n:~ d + o 
a·- Merch, Sharp and Dohm<-), West Polnt, Penns·;lvania. 






Uslng pipets and volumetric flasks, admixtures for each 
drug formulation in the two infusion fluids \<Jere prepared ir, 
varying concen~rations. The resulting solutions were stored 
a-r room temperature, with normal I ight exposurE'J. 
A Bausch and Lomb Spectronic 600a Double Beam Spectro-
photometer, providing an incident beam wavelength ran~1e of 
220 to 320 mi 1_1 imicrons, was used to measure the absorbance 
determined by the diluent of the admixture sample. An attachod 
L!near/Log Varicord 43b Recorder provided continuous recording 
of the ultraviolet spectrum showing the wavelength· of maximum 
absorption CAma><). 
The optimum spectrophotometric concentration for each 
drug fcrmulatlon was determined from the concentration of 
fhose admixtures which demonstra·ted an absorbance range of 
between 0.2 and 0.9. At 4 and 8 hours after initial admixture, 
the absorption spectra tor these solutions were redetermiGed. 
The optimum spectrop~otametric concentration for the drug 
forrnulatlQns was considerably less than the usual therapeutic 
conce1·:1~rc.i"ion of the components o-f the ::1dmix-rur0 used ir1 
ciinico! pructice. 
Tne absorbance values obtained were _used to plot Beer's-
Law curves for each drug formulation in both Sodium Chloride 
a- Bausch and Lomb Optical Co., Rochester, New York. 




Injection and 5% Dextrose Injection a·t ! , 4, and 8 hour 
intervals. At the same time intervals, the pH of a thera-
peutic concentration of each drug in both Sodium Chloride 
lnjeci·ion and:;% Dextr·ose Injection was measured using a 
Corning Model 7a pH Mater. 
Two component admixtures were prepared in Sodium 
Chloride Injection and 5% Dextrose" Injection contai-ning 
metaraminol bitartrate in combination with each of six 
c:or·ticcster·iods; prednisolone sodium phosptHde, dexamethasone 
sodium phosphate, methylprednisolone sodium succinate, hydro-
cortisone, hydrocortisone-21-phosphate, and hydrocortisone 
sodium succinaie. 
Malntaini~g the same order of mixing, mat2raminol bitar-
trate was added, using graduated pipets, to volumetric flasks 
containing Sodium Chloride Injection. The flasks were 
stoppered and shaken thorough!~. To each of these solutions, 
one of the corticosteriods mentioned previously was added, 
the flask stoppered and again shaken. The same admixture 
s e q u 'J n c (:) v1 a s f o i I o w E-) d w h e n -t" h e d e x t r o .s e s o I u t 1 o n s e r v e d a s 
the di lucnt. The resulting admixtures WE:~re colorless and 
•t~ere storod at room temperature with normal I igrrt exposure. 
At i, 4, and 8 hours after initial admixture, the pH of these 
admixture~ was recorded. 
After inspection for any visible changes (precipitation, 
·-------· ----------·----
a - Co r r. i n g S c i e n t i f i c I n s ·t-r- u rn E~ n-!" s > Co r n i n g , New Yo ,. k . 
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co I o r· c h a n g e , g a s e v o I u t i o n ) , a I i q u o t s ·f r· om e a c h a d m f x t u r· G 
wer·e vlii"hdra\'lrl and ·diluted in volumetric flasks to produce 
the op-timum spectrophotometric concentration for each of the 
admixture components. This procedure was followed at each 
of the specified time intervals. 
Solutions to be used in the reference beam of the 
spectrophotometer were prepared for each admixture component. 
The composition of the reference solution was identical to 
----
-that of an --i n d i-vTd_u_ar-6)m p6-ner=,t -~,-1 i rh i n tf!e -d i i-ui"ea- ad m i ><; i ure-; 
By alternating the reference solutions, a differential spectr·o-
photometric analysis was per·formed on each of ·t-he dliuted 
admixtures obtaining the ultraviolet absorption spectrum for 
each drug component at I, 4, and 8 hours afi'er therapeutic 
admixture. Variations from the standard spectrum, either as 
an appreciable change in absor-bance or· in i·he development of 
secondary peaks, were considered to suggest the occurrence of 
a chemical interaction. 
The absorption spectrum obtained for each drug formulation 
after admlx:ture is shown in the figures which follow. The 
speci-r-um r·epresents the average va I ue of three reo I i cate~-; for 
each admi)(TUrt-J combinc:dion. To provide a visual ::ornpar·ison, 
th0 standard or reference spectrum of the same drug in the 
same. cc;ncentration and diluHnt is olso pr-ovided. included in 
-~he !t~SJsnds which accompany the ultraviolet spectr-urn are the 
\m a x 1 a d rn i x t u r e co n c e n tr a t i o n , r e f e r e n c e s o I u t i o n u s e d i n 
spectrophotometric analysis and the time interval which th~ 
spectrum ~as obtained after admixture. 
~-
The standard spectrum for each drug formulation was 
determined from the Beer's-Law curves obtained in the pre-
liminary vwrk. The graphs that follov-1 contain -t-he plotted 
Beer 1 s-Law curve for each drug formulation in both Sodium 
Chloride Injection and 5% Dextrose Injection. 
pH values obtained for the therapeutic admixture and 
the individual components are r~corded In the tables that 
foi lo1·1. A summary of the results o·f the adml:x:ture analysis 
CHAPTL:H I I I 
RESULTS 
In each of the admixtures described In this section, 
the medicinal agents were combined with the two infusion 
fluids) 5% Dextrose Injection and Sodium C.hloride Injection, 
-------------
in concentrations resemb-lrrig-those emplo~'ed ir1-c1Tr1rcal-
application. Because the resulting admixtures were too 
d e n s e , o p t i c a I I y , f o r ex a rn i n at i o n i n t h e c? p e c t r o p h o torn e t e r , 
it was necessary to dilute aliquot samples to concE~ntrati()ns 
which would produce clear spectra throughout- the U.V. rC'Inge. 
T h e f i n a I d i I u t i o n s w e r e rna d r:J o t I .• 4 , a n d 3 h o u r s a f t e r 
!nltial admixture, immediately prior to scanning, so as to 
p'rovide the maximum opportunity for a reaction to occur. !n 
this way both physical and chemical changes could b9 observed. 
Measurements of the pH of the original admix·tures \•/err-.: 
a 1 s o m a d 8 0 t -r h e I , ·,.1 , a n d 8 h o u r i n t e r v a I s . T h e r e s c. I ·1· s o t 
these observations are summarized in the tables accompanying 
the description of each admixture. 
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Metaraminol Bitartrate and Prednisolone Sodium PhoE.PJ:l~~.J.!.~ 
§ o'd'TiJ'rrlchT6 I i de I n j e c t i 0 n 
Metaraminol bitartrate, 500 mcg./ml., and prednisolone 
sodium phosphate, 100 mcg./rnl., were mixed in Sodium Chloride 
Injection. Dilutions of the admixture were made to provide a 
concentration of 40 mcg./ml. for metaraminol bitartrate and 
8 rncg./ml. for prednisolone sodium phosphate. 
The absorption spectrum of the admixture ~as compared 
-vi-i-t-h----t---h-e--s-t-a-n-d-a-r-6 ____: s t3 e e-t-r-u-m---et-n d---- d erno n-s 1- r-ated thr-~- rlAve Looment .. - - - . - . -, - --------------
of a secondary peak for predniSolone sodium phosphate. This 
altered absorption spectrum would be suggestive of a change 
in this component. The absorption spectrum for metaraminol 
bitartrate was not altered appreciably throughout the eight 
hours of study (Figures I, 2, 3). 
Measurements of the pH revealed only minor changes ln 
the admixtu~e during the period of study. The pH of the 
admixture was quite acidic, approximating that of metaraminol 
bitartrate wi·thout the presence of the corticosteroid 
(Table I), 
Table I: pH Change of Metaraminol Bitartrate and Pred-




pH after admixture 
I hr. 4 hr. 8 hr. 
·---- -~-------"·--·-·--------~ 
Metaraminol Bitartrate and 
Prerlnisolone Sodium Phosphate 
Sodium Chloride Injection 
500 
100 
Me't"aramlno! Bitar-trate 500 





3.7 3 7 . ( 
6.4 6.4 
3.7 .3. 6 












10 20 30 40 ' 50 60 
Concentration (mcg./ml.) 
Gr-aph I. Bee!- plot for- Metaraminol Bitar-t-rate in 
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Graph 2. Beer plot for Prednisolone Sodium Phosphate 
in Sodium Chloride Injection. 
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Met a r a m i no I B i t a r- "!" r a t e a n d P r e d n l so I o r.!._?-__ S ~-~LJ__Il2_ P-~~-_:; p h a i~-~­
? if; De ~j'o~-~.J.. n j e C::.! ion 
Using 5% Dextrose Injection as the diluent, metar·aminol 
bitartrate and prednisolone sodium phosphate were mixed at a 
co n cent rat i o n of 50 0 m c g • I m I • a n d I 0 0 m c g • I m I • res p e c t i v e I y . 
As viith the previous sodium chloride admixtures, dilution of 
aliquot samples was necessary to provide the op1·imum spsctro-
photometric concentration of 4G mcg.lrnl. for metaramln0l 
____t.,_l ta_e_!_e_aJ:e _a_rJ_(j__§_ITl_~g_._/_mJ_. _ _fe>_~ p redn I S(J I o~e -~odIum p hospha!~. 
The absorption spectrum for the components of this admix-
ture compared quite favorably with the results of the admixture 
analysis for the saline admixtur·es. Prednisolone sodium phos-
phate demonstr-ated a remarkably similar secondary peak, whi ie 
the absor·ption spectrum for metaraminol bitartrate remained 
unaltered. I 1· •tt o u I d a p p e a r ·t h a t t h e i n f I u e n c e o f t h e d I I u t i n g 
solutions selec·t·ed was minimal (Figures 4, 5, 6). 
The pH values recorded for the therapeutic admixture and 
the individual components closely paralleled the v~lues obtained 
for the saline admixtures (Table il). 
Table II: pH Change of Metaraminol Bitartrate and Prednis•.)lone 
Sodium Phosphate in 5% Dextrose Injection. 
--~ ... ------------·-· ·-~-----·----· ______ ,._ ... 
Component 
Metaram!ncl Bitartrate and 
Prednisolone Sodium Phosphate 
51 Dextrose Injection 
cone. 
(meg. /m I • ) 
500 
100 
Metaraminol Bitartrate 500 
Prednisolone Sodium Phosphate 100 _________ .. _______________________ _ 
pH after admixture 
I hr. 4 hr, 8 hr. 
3.8 3.9 3.9 
4.9 4.9 4. 9 
3.6 3.6 3.6 
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Graph 4. Beer plot for Prednisolone Sodium Phosphate 
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Metararnl no I Bi tartl-ate and Dox•:Hnethasone Sod i urr. 1-'ho~.~ohcli"o in 
.. ..---.. --~ ............ ~----~·~--~·------- ... --"'~~----- ... ------·--·----~-----~-··-··.:.------~-·--·--·-,-.-.---~-----·-·· .. ·-··~---L-.-·-- ··--•·-- .. ·-
5 o .i~L!.~_S..0.J.2.E .. i:.9 o _._! n j e ~-:~J5!..~ . 
Met a ram i no I b i t a r· -r rate , I 0 0 rn c ~J • I rn I .. , a n d de~< am e t h a son o 
sod i u m phosphate 1 2 0 m c g • I m I • 1 were m i xo d i n Sod ,l u m C h I or 1 do 
I n Je c t I on • From the Bee r p ! o t s o b t a i ned i n i t i a i I y , the opt i m urn 
spectrophotometric concentration for metaraminol bitartrate 
wa!3 determined to be 40 mcg./ml. and 8 mcg./ml. for doxamotha--· 
sone sodium phosphate. 
____ _Ib_e __ a_t.>S_o_r_[Jj_jg_n __ s_p_eciT um obta i ned W('l s corr~p a rod ~; !_1' h _the 
s t a n d a r d s p e c t r· urn a n d d em o n s i" r a t e d a s h l f t i n t h. o ~. m a x ;:: n d 
.loss of absorbance 'for de)(a·methasone sodium phospr1atc. Tl1is 
altered spsctrum would be suggestive both of a loss of con-
centratlor and a change in the chemical structure for this 
wes not altered appreciably (Figures 7 1 8, 9). 
AdmixTures of these two therapeutic agents, in Sodium 
Chloride Injection, produced a rather acidic solution which 
s h o vl C-3 d i i t t I o v a r i a t i o n o v e r t h EJ p e r 1 o d o t t· 11 e s t u d y 
(Tablo ! i I). 
T ~1 b I ~~ I I I : p H C h a n g e o ·f ~1 o t a r a m i n o I t3 1 t a r t r· a -r e a n d D ex a ·• 
mc-;thasone Sodium Phospha-t-e in Sodium Chl0rido lnj~:.:ction, 
cone. 
(mcg./rnl,) 
p~ afi·er admfxtute 
! hr. 4 hr. 8 hr. 
~vletaraminc.! Bitartrate and 100 
Dexam~:dh-:1~;cne ~iod i urn Phosphate 20 
4 .7 4.a 4 • (~ 
Sodium Chloride Injection 6.4 6.4 6.4 
tvletoraminol Bitartrate 100 ~). 9 3.9 3,9 
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Graph 5. Beer plot for Dexamethasone Sodium Phosphate 
in Sodium Chloride Injection. 
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Meta r·am 1 no I B i i"a rtrate and Dexamethasone S_ od i u_m Phosphat_e in.
5-% D e_~_t r· c~~-! n j e c.:!: i o n 
The admixture of metaraminol bitartrate, 500 mcg./ml ., 
and dexamethasone sodium phosphate, 100 mcg./ml., in 5% 
Dextrose Injection, represented a concentration which was 
five times greater than the previous admixture containing 
Sodium Chloride Injection as the diluent. The concentration 
rati<;>, 5:1, however, remained the same. The optimum spectra-
hotometric concentration used to obtain the absorption 
spectrum also remained the same; metaraminol bitartrate, 
40 mcg./ml., and d8xamethasone sodium phosphate, 8 mcg./ml. 
The absorption spectrum determined for each drug com-
ponent resembled the spectrum bbtained for the components 
when admixed at a lower concentration. Dexamethasone sodium 
phosphate demonstrated a shift in the ~max and a loss of 
absorb<..'lncep 1vhlle metaraminol bit.artraie remained appr·eciably 
unchanged <Figures 10, II, 12). 
It was noted that the increased concentration of each 
drug component did not create an appreciable alteration in 
the pH va I ues ,for either the i nd i vi dua I drug components or 
the therapeutic admixture (Table IV). 
Table IV: pH Change of Metaraminol Bitartrate and Dexa-
methasone Sodium Phosphate in 5% Dextrose Injection . . - _________ _.. ___ ...... ____ .......__ ........ _ 
cone. pH after admixture 
Component (meg. /m I . ) I hr. 4 hr. 8 hr. 
--.--~--... ,..,._ _ _ _..... 
Metaraminol Bitartrate and 
Dexamethasone Sodium Phosphate 
5% Dextrose Injection 
Metaramlnol Bitartrate 





5.0 5. I 
5.0 5.0 
3.6 3.6 
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Graph 6. Beer plot for Dexame-t-hasone Sodium Phosphate 
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Metaraminol Bitartrate and Methvlprednisolone Sodium 
Succinate in Sodium Chloride lnJ<:ction ___ _ 
Metaraminol bitartrate, 400 mcg./ml., and methyl-
prednisolone sodium succinate, 125 mcg./ml., were mixed in 
Sodium Chloride Injection. Within four hours a precipitate 
developed in this admixture. Therefore, aliquots .• at the 
stated time Intervals, were withdrawn by using a Swinnex-25,a 
0.22.rnicron membrane fi Iter. Dilution of these fi ltcred 
~-----"-'I Lq_U_o_f_s~P-LDV I ded the optimum spectr-ophotornotr l c concentr·a-
.··rion for- each component; metaraminol bitartrate, 40 mcg./ml., 
and methylprednisolone sodium succinate, 12.5 mcg./ml. 
Comparison of the absorption spe~trum obtained with the 
standar·d spectrum demonstrated an appreciable 'loss of absor--
bance for methylprednisolone sodium succinate, suggesting a 
reduction in the concentration for this component. The 
absorption spectrum for metaraminol bitartrate also demon-
strated a minor loss of absorbance (Figur-es 13, !4, 15). 
The pH of the admixture, which remained constant through-
ou·r the study, assent i a I I y resemb I ed the in it i a I pH of meta ra--
minol bitartrate (Table V). 
----------·-------
a - ~~iII l por·e Corp., Bedford, Massachusetts. 
L 
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Table V: pH Chango of Metaraminol Bitartrate and Methyl-
prednisolone Sodium Succinate in Sodium Chloride Injection. 
Component 
------------------------
Metaraminol Bitartrate and 
Methylprednisolone Sodium 
Succinate 











pH after admixture 
I hr. 4 hr. 8 hr. , _____...__. ___  
3.8 3.8 3.8 
6.4 6.4 6.4 
3.6 3.6 3.6 
7. 3 7,3 7.3 
---------·--·-·----
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Graph 7. Beer plot for Methylprednisolone Sodium 
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' I l I I I i l 
260-~·- 25c, 3oo .3§*o ___ , 
V/ .. ~ 'IE JENGTH _ m i : i ; t·a 1 ct-ons 
Methyip~ed~(solone ~odium 
Succ:na[e .,2.5 rncg.(ml. 
ref: Me)taramtnol Bitartrate 
40 mcg./ml. 
~-l}:~\.'ELE(\G"T'rl.~ m' ~ ! (r:11 crcns 
Metaraminol Bitartrate 4Q mcg./ml. 
ref: Methylpredniso;one Sod(um 
Succinate 12.5 mcg./ml. 
Figure !5. U.V. Spectrum of Metaram!hot 
nlsolone Sodium Succinate <Amax 248 m~) 
I • 
B i t a r t r a t e ( Am a x 216 7 r.1 iJ ) w i t h Met h y l p r e d ~ 
in Sodiu~ Chloride Injection at eight hours. 
\.n 
!'0 
Metaraminol Bitartrate and· Msthylprednisolone Sodium 
§_~cc·i na~~n 5%Eiextrose 1 njec·;·J~.~ . ·----.--
53 
A precipitate was observed within four hours after the 
mixture of metaraminol bitartrate, 400 mcg./ml., and methyl-
prednisolone sodium succinate, 125 mcg./.ml., in 5% Dextrose 
Injection. Filtered al iquots were withdrawn from the admix-
ture and dl !u!ed to provide a concentra·rion of 40 rncg./ml. 
fot- rrtetaraminol bitartrate and i2.5 mcg./ml. for methyl-
l.n comparing the absorption spectra for the two drugs 
after admixture, it was noted that an appreciable change 
occurred in the spectrum for methylprednisolone sodium 
-succinate. The loss of ab·sorbance observed for this component 
~ould suggest a reduction in concentration~ A minor loss of 
absorbance was demonstrated for metaraminol bitartrate, The 
results of this admixture analysis and that of the saline 
admixture would strongly suggest that the precipitate con-
sisted primarily of the corticosteroid component (Figures 16, 
I 7, I 8) • 
The admixture pH for this drug combination approximated 
the initial pH recorded for metaraminol bitartrate. The pH 
change for methylprednisolone sodium succinate in the dextrose 
admixture was observed to be slightly less than in the sal in('' 
admlxture. It was noted that the loss of absorbance for this 
component was also correspondingly less in the dextrose admix-
t u re (Tab I e V I ) . 
54 
Table VI: pH Change of Metaraminol Bi·tartrate and Methyl-
prednisolone Sodium Succinate in 5% Dextrose lnject!on. ---· ....;..... ______ _ 
cone. pH after admixture 
Component (mcg./ml .) I hr. 4 hr. 8 hr. 
---·----------------------------------·--~-----·----------------------------
Metaraminol Bitartrate and 
Methylprednisolone Sodium 
Succinate 









4.2 4.2 . 4. 2 
5.0 5.0 5.0 
3.6 3.6 3.6 






G r- a p h 8 . 8 e e r- p I o t . f o r tvi e t h y I p r e cl n l s o I o n e ~~ o d i u m 
Succinate ln 5% Dextrose Injection. 
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Metaramin6! Bitartra·te and Hydrocortison~ In Sodium Chloride 
I r:_ J e cT·i on~-- ·--·--·-·-
An admixture of metaraminol bitartrate, 500 mcg./ml ., 
and hydrocortisone, 250 mcg./ml., was prepared in Sodium 
Chloride Injection. Aliquots were withdrawn from this admix-
ture and diluted to provide the optimum spectrophotometric 
concentration for each drug component. This concentration was 
3 0 m. c g . I m I • f o r met a r am i no I b i t a r t r a t" e a n d · I 5 m c g • /m I • f o r 
hydrocortisone. 
Admixture analysis provided an absorption spectrum for 
each drug component which demonstrated no appreciable change 
for either metaraminol bitartrate or hydrocortisonFJ through-
out the eight hours of study (Figures 19, 20,.21). 
Gecause of the acidic nature of the hydrocortisone com-
ponent, th9 pH change was of a lesser magnitude than that 
observed for the other corticosteroid containing admixtures 
(Table VII). 
Table VI I: pH Change of Metaraminol Bitartrate and Hydro-




pH after admixture 
I hr. 4 hr. 8 hr. 
·----·------·----------·---·· 
Metaraminol Bitartrate and 
Hydrocortisone 








3.6 3.6 3.5 
6o4 6.4 6.4 
3.7 3o7 3.6 
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Metaraminol Bitartrate and Hydrocortisone in 5% Dextrose 
} n j e ~:_} 1 c)rl ----
At a concentration o.f 500 mcg./ml. and 250 mcg./ml., 
64 
respectively, metaraminol bitartrate and hydrocortisone were 
admixed in 5% Dextrose Injection. Admixture analysis was 
performed on aliquots of this mixture which contained 15 meg./ 
mi~ The absorption spectrum obtained from this analysis 
para_lleled the results of the saline admixture. Admixture 
of these two components at the specified concentrations does 
not present evidence of any recordable chemical interaction 
(Figures 22, 23, 24). 
Measurements of pH in this admixture closely paralleled 
those noted when the sa.l ine solution was used as the infusion 
solution (T;.lble VIII). 
Table VI:!.: pH Change of Metaraminol Bitartrate and Hydl~o­
cortisone In 5% Dextrose lnjeciion. 
~-·----~-----·------------------·· ·-·~--·------· 
Component 
Metaraminol Bitartrate and 
Hydrocortisone 









pH after admixture 
I hr. 4 hr. 8 hr. 
3.8 3.8 3, 8 
5.0 5.0 5 ·• 0 
3.6 3.6 3.6 
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Figure 24. U. V. 




Metaraminol Bitartrate <Amax 2 7 m~) with Hydrocortisone 




Met a Cam ~~~~.I B i tartrate at"!~ d r-oc or i" i son e- 2 I -Phosphate i 12. 
§odium Chloride lnjec!_ion ·. · 
Metaraminol bitartrate, 500 mcg./ml., and hydrocortisone-
21-phosphate, 250 mcg./ml., were mixed fn Sodium Chloride 
Injection. Aliquots were withdrawn from this admixtur'e at 
specified time intervals as before and diluted to obtain the 
optimum spectrophotometric concentration for each component. 
This.concen'!-ration was 30 mcg./ml. for metaraminol bitartrate 
a n d i 5 m c_9 • I m I • f o r h _y_<:l_ro c_Q_r_ii_§_()_ n e_··_2j : f:'Jl <2_ ~pJla !_e__. ____ _ 
Comparison of the absorption spectrum with the standard 
spectrum demonstrated no appreciable change for either metara-
minol bitartrate or hydrocortisone-21-phosphate throughout the 
eight hours of study (Figures 25t 26, 27). 
In the admixtures previously studied, a pH change Of the 
magnitude seen here was associated with an altered absorpi·ion 
spectrum suggesting the occurrence of a chemical interaction. 
It would appear that the stabi I ity of hydrocortisone-21-
phosphate ln this admixture was not influenced by a pH change 
(Table IX). 
Table IX:: pH Change of Metaraminol Bitartrate and Hydro-
cortisone-21-Phosphate in Sodrum Chlo~ide Injection. 
cone. pH after- admixture 
Component 
-------------·---------------
Metaraminol Bitartrate .and 
Hydrocortisone-21-Phosphate 
Sodium Chforide Injection 
~1et11 rami no I B ita rt rate 
Hydrocortisone-21-Phosphate 





I h r . 4 hr. 8 hr. ..... ---A.;;,.,.-----
4.0 4,0 4.0 
6 .t> 6.4 6.4 
3.7 3.7 3.6 
7. 4 7.4 7. 4 
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Metaraminol Bitartrate and Hydrocortlsohe-21-Phosphate in 
~~ .. D e.~.:.t.~.?~~ J~~-:-FT o!!. . . 
Metaraminol bitartrate and hydrocortisone-21-phosphate 
were mixed inS% Dextrose Injection at a concentration of 
500 mcg./ml. and 250 mcg./ml ., r~spectively. Admixture 
ana1ysis was performed on the diluted aliquot samples which 
provided a concentration for 30 mcg./ml. for metaraminol 
bitartrate and 15 mcg./ml. for hydrocortlso~e-21-phosphate. 
__ A_s_ wl th the sa I !_ne_~cl_rn_i_~!u__r-_e, __ no a_pfl r:_El_c_i_a_l:> J _e _ c;ha_ 12-ge __ ~"---­
the absorption spectrum for either metaraminol bitartrate and 
hydrbcortisone-21-phosphate occurred throughout the eight 
hours of study (Figures 28, 29, 30). 
P1gain, the marked drop in pH, with reference to the 
corticosteroid, did not appear to be associated with an altera-
tion in the absorption spectrum for this component (Tjble X). 
Tab!e X: pH Change of Metaraminol Bitartrate and Hydro-





pH after admixture 
I hr. 4 hr. 8 hr. 
------·-·~-----·---...------- ------·-·-·-··-·-·-
Metar~mlnol Bitartrate and 
Hydrocortisone-21-Phosphate 












5, 0 5.0 
3.6 3.6 
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Graph 12. Beer plot fo-r Hydrocortisone-21-Phosphate 
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m i l i t microns 
Hyd~oc4rtisone-2!-Phosphate 
15mcg:./m!. 





U.V. Spectrum of Metaraminol Bitartrate 
( max.248 mu) in 5% Dextrose Injection 
( max 267 mu) with Hydrocortisone-
at elg(1t hours. 
-...! 
(X) 
Metaraminol Bitartrate and Hydrocortisone Sodium Succinate 
Til-so·aTufi1c-~·lcre--Tiij--ec=Fi on-----
A precipitate was observed w1thin one hour after 
metaraminol bitartrate, 500 mcg./ml., and hydrocortisone 
79 
sodium succinate, 250 rncg./ml., were mixed in Sodium Chloride 
Injection. Therefore, aliquots at the specified time inter-
vals werE! vdthdrawn by using a Swinnex-25 filter. Dilution 
of thes9 ·f i I tared a I i quots was ca I cuI a ted to provide tho 
optimum spectrophotometric concentration for each component 
had no precipitation occurred, metaraminol bitartrate 30 meg./ 
mi. and h-ydrocortisone sodium succinate 15 mcg./ml. 
The absorption spectrum obtained was compared to the 
standard spectrum and demonstrated an appreciable loss of 
absorbance for hydrocortisone sodium succinate. This would 
suggest an appreciable reduction in concentration for this 
component. Metaraminol bltartrate demonsi·rated both an 
altered absorption spectrum and a loss of absorbance. The 
·i m p o s s i b i I i t y o f u s i n g a r e f e r e n c e so I u t i o n i n a co n c e n t r a -
tion to compensate for the loss of the hydrocortisone component 
was the probable cause of the altered spectrum seen for metara-
m i no I ( F i g u res 3 I , 3 2 , 3 3 ) . 
The pH of the therapeutic admixture at specific time 
inter-vais after initial mixing VJas compared to the pH of the 
individual components. It was noted that the pH ot the 
admixture was somewhat greater than three pH units below that 
seen with the corticosteroid, in the absence of tho pressor 
agent (Table XI). 
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Table XI: pH Change of Metaraminol Bitartrate and Hydro-
cortisone Sodium Succinate in Sodium Chloride Injection. 
Component 
Metaraminol Bitartrate and 
Hydrocortisone Sodium 
Succinate 








pH after admixture 
I hr. 4 hr. 8 hr. 
·-------
3.8 3.8 3.8 
6.4 6.4 6.4 
3.7 3.7 3.6 
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Graph 13. Beer plot for Hydrocortisone Sodium 
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fvletaraminol Bitartrate and Hydrocor-~ison~ Sodium Succinate 
"tr1 5%.Dex.7rrose Injection 
The admixture of metaraminol bitartrate, 500 mcg./ml. 
and hydrocortisone sodium succinate, 250 mcg./ml. rn 5% 
Dextrose Injection demonstrated the presence of a precipi-
tate after one hour of admixture. Filtered al lquo~s were 
withdrawn and diluted to provide a concentration of 30 meg./ 
mi. for metaraminol bii·artrate and 15 mcg./ml. for hydro·· 
c6rtisone sodium succinate, based on calculations which 
ignored the formation of the precipitate. 
Comparison of the absorption spectrum obtained with the 
standard spectrum demonstrated an appreciable loss of absor-
bance for hydrocortisone sodium succinate, suggesting an 
appreciable reduction of concentration for this component. 
The loss of absorbance for this component in the dextrose 
a d m Lxt u r e vi a s s I i g h t I y I e s s a n d d e v e I o p e d m o r e s. I o vi i y t h a n 
o b s e 1- v e d i n the sa I i n e a d m i x t u r e . tv1 eta r a rn i no I b i -r a r t rate 
demonstrated both an altered absorption spectrum and a loss 
of absorbance. As with the saline admixture, no effort was 
made to compensate for the loss of the hydrocortisone com-
ponent by altering the concentration of the reference. This 
fai !ure was the probable cause of the altered spectrum seen 
tor metaram i no I.. The data obtai ned from both the sa I i ne and 
dextrose admixtures would suggest that the precipitate con-
sisted primarily of the corticosteroid component (Figures 34, 
35, 36). 
In this admixture, the development of the precipitate 
was somewhat slower than wJth the same combination i~ Sodium 
86 
Chloride Injection. The alteration in pH, using Dextrose 
Injection as the infusion fluid, was slightly less than seen 
in the saline solution (Table XII). 
Table XII: pH Change of Metaraminol Bitartrate and Hydro-
cortisone Sodium Succinate in 5% Dextrose Injection. 
Component 
·----···--------~------






pH after adm'ixture 
I hr. 4 hr. 8 hr. 
4.0 4. I 4, I 
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Tabie XI! I: Summary of the Spectrophotometric ,;\na!ys!s on Admixt!:Jt-es Conta(.ning 




~ ~ • r· ~ ,. ·~ -'- ,.... '. h t 1,., + - • -.._or:c. in "'f''::l'--l,op,o Olii8.llo._. 
j • ¥ . *.,I ac-r.:lxi'ur-e' conc.·,...l 
Admixture 'mrq' ;'""t' 1 f,~.··cn /rr,fl '1 . \ .. ~ __ •••. _., '1''-':::;•ti.l,l. spectrum*** 
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Prednisolone Sodium Phosohate 
. ' 
Metaramirioi Bitartrate 
Dexamethasone Sodium Phosphate 
!~~leta rami no I Bitartra-te 
Methylprednisolone Sodium Succinate 
Meta rami no l Bitartrate 
Hydr·ocortisone 
tv1eta rami no I Bitartrate 
Hydrocortisone-21-Phosphate 
Metcraminoi 8 ita r·trate 
Hydrocortisone Sodium Succinate 







































*The concentration of the admixture components ref~ects a th~rapeutlc concentration 
which could be added to 1000 mi. of infusion solution. : 
i 
**The optimum spectrophotometric concentration 
produce an absorbance between 0.3 and 0.9. 
is +he concentnation ra1ge which would 
. i 
***Alteration in absorption spectrum was considered significant If an appreciable loss 
of absorbance or chang~s In the continuous absorption spectrium occurred. 
*'***Failure to use a reference solution, in a concentr-ation 
t~e hydrocortisone component, was the probable cause of 
metaraminol. 
to ompensate for the loss of 
the altered spectrum seen for 
\0 
II I' I 
Table XIV: Summary of the Spectrophotometric Analysis on Admixtulres Containing Metaraminol 
Bitartrate and Selected Corticosteroids ln 5% Dextrose. !njecticn. 
. optimuJ 
cone. in spectrophotdmetric 
admixture* cone.** 
.A.dmixture (mcg./ml .) 
-----···----------- ----------·----~--
Prednisolone Sodijm Phosphate 
Me·taraminol Bitartrate 
Dexamethasone Sodium Phosphate 
Metaraminol Bitartrate 






Hydrocortisone Sodium Succinate 
Metaraminol Bitartrate 
I (In . ...., ....... 






































a I tered**** 
*The concentration of the admixture components reflects 
which could be added to 1000 mi. of infusion solution. 
a therapeutic concentration 
I 
I 
**The optimum spectrophotome~ric concentration is the concentnation range which would 
produce an absorbance between 0.3 and 0.9. 
I 
***Alteration in absorp~ion 
of absorbance or changes 
spectrum was considered significan~ if an appreciable 
in the continuous absorption spect~um occurred. 
{QSS 
****Failure to use a reference solution, in a concentration 
the hydrocortisone component, was The probable cause of 
meta rami no I . 
! 
to ~ompensate for the loss of 
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CHAPTER IV 
DISCUSSION 
The use of the sympathomimetic pressor amines and the 
glucocorticosteroids is currently being advocated for the 
t rea t me n t o f c a r d i o g e n i c s h o c k " T h e i n·t r a v e no u s u s e o f 
these drugs, either singly or in combination as components 
of an intravenous admixture, has been shown to provide a 
rapid and continuous increase in blood pressure which results 
In a fDvorable perfusion of the heart, kidneys, and brain. 
T h e r a r i d r e s to r a t i o n o f b I o o d p e 1- f u s 1 o n to t h e s e o r g a n s h <.:: s 
reduced the morbidity of this syndrome (34, 35). 
Chernl:.::a!iy, drug formulations of the sympathomimetic 
pressor arninss nre acidic (pH 3-4), while formulations c~1n~ 
taining the corticosteroids are generally more alkaline 
(pH 5-8). The s imu I taneous use of these drugs as cornponents 
of an Intravenous admixture could result in a pH range which 
mfght adversely affect the stabi I ity of either or both of 
these e:1g<~n'i-s. Because of their c I in i ca I US(:> and pass i b I e 
chemical reactivity, ~opresentative drug formulations from 
each group were chosen for this study. 
f\·fter- an initial spectrc•photometrlc screening, met-araminol 
bitartrate and six corticosteroids, including three different 
drug formtJ!atlons of hydrocortisone, were selected. Admixtures 
coni"<Jlning these drug formulations could be mixed at a 
93 
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therapeutic concentration and diluted to provide ihe necessary 
optimum spectrophotometric concentration for boi·h components 
vdthou"f altering the initiul therapeutic concentration ratio. 
Sodium Ch!oride Injection and 5% Dextrose Injection were 
selected as the dilution vehicles because of their clinical 
use bnd lack of appreciable buffering capacity. 
The criterion used to judge the occurrence of a chemical 
i n t e r a c t i o n · w a s a n a I t e r· a t i o n i n t h e U • V • a b so r p t i o n s p e c t r u m 
ab:;orbance wou I d indicate a cort-espond i ng loss of concentra-· 
tlon. Changes in the continuous abs6rption spectrum, such as 
a shift in the ~max or development of secondary peaks, would 
Indicate an alteration in the chemical structure for the drug 
f o rrnu I en i on , 
Obtaining the absorption spectrum specific for each drug 
co;nponent in an admixture pr-esented a prob !em in that the 
presence of two different drugs in solution can produce an 
absorption spectrum which is a composite of the individual 
spectrum for each drug. The method used in this study to 
effectively mask or block the presence of one admixture com-
ponent was the technique of differential spectrophotometric 
ana!ysls. In this, the solution in the reference beam of the 
spectr-ophotometer, is the same composition and concentration 
as one component of the admfxture tested. By alternating this 
reference solution, the absorption spectrum specific for each 
drug component can be obtained. 
The importance of Gsing a reference solution of appropriate 
composition was demonstrated by the absorption spectrum 
obtained for admixtures of metaraminol bitartrate and hydro-
cortisone sodium succinate. In these, the precipitate 
observed was believed to be composed prirnari ly of the corti-
costeroid component. Failure to use a reference solution to 
compensate for the apparent loss of this component resulted 
in an altered for composite spectrum observed for metaraminol 
bitartrate. 
after admixture were recorded at specific intervals. Through-
out the study, the pH of admixtures represented in the order· 
of two to more than -t"hre0 pH units of change for the corti-
costeroid component. The pH change for metaraminol did not 
exceed one pH unit. Comparison of the changes In pH with the 
rf~s u·i ts obta l ned by spectrophotometric ana I ys is of the same 
admixture c~mponents suggested some possible correlation. With 
the exception of admixtures containing metaraminol bitartrate 
and hydrocortisone or hydrocortisone-21-phosphate, a pH change 
of three pH units for an admixture component was associated 
with an alteration in the absorption spectrum for the same 
coinponent. 
Three different drug formulations of hydrocortisone were 
used In the study, hydrocortisone, hydrocortisone~21-phosphate, 
and hydrocortisone sodium succinate. Each was mixed with 
metaraminol bitartrate in the s2me hydrocortisone equivalent 
concentration. Admixtures containing hydrocortisone demon-
strated a change of two pH units for this component and no 
appreciable alteration in the U.V. absorption specrrum. 
/\dmixturos containing hydrocortisone-21··phosph<de derncHlsi"rah>-d 
a 3 p H u n it c h a n g e a n d a s I i g h t I o s s o f a. b so r p "f l o n i n t h e a b so r p ·· 
tion spectrum was observed. Hydrocortisone sodium succ!nate 
containing admixtures demonstrated a 3 pH unit change for thls 
cornponerd cHid a p roc i pi tate was Ob·servr:>.d. 
It would appear that dlfrereni drug formulations of the 
same parent compound could have quite different stabl I lty 
charecterlstlcs after admixture. 
CHAPTER V 
SUMMARY AND CONCLUSIONS 
The purpose of this investigation was .to demonstrate the 
of spectrophotometric analysis in detecting the occurrence 
of chemical interactions between t_wo drug components of an 
Intravenous admixture. 
was obtai~ed for each drug formulation before and after admix-
t u r e . Corn p a r i son of the res u I tan t spectrum was made for a 
\ 
change in absorb~nce at the Ama~, and for alteration or shift 
of tho ~max. ·The occurrence of a chemical interaction was 
" . . I s ugges T~3c when on appreciable loss of absorbance at the ~max 
occurred~ This would indicate a loss of concentra~ion for the 
dfug component .. An alteration of the absorption spectrum with 
the development of a new or secondary lmax would suggest modi-
flcations in the structural nature of the drug component and 
would also be suggestive of a chemical interaction. 
Of the twelve admixture combinations containing metaraminol 
and one of six selected corticosteroids, eight admixtures 
demonstrated evidence of chemical interaction. 
Admixtures of metaraminol bitartrate with hydrocortisone 
sodium succinate and methylprednisolone sodium succinate in 
Sodium Chloride Injection and 5% Dextrose Injection prod~ced 
precipitates within one and four hours respectively. Subse-
queni" analysis of fl ltered admixture samples demonstrated a 
97 
98 
considerable foss of absorbance tor the corticosteroid 
component. 
Admixtures of metaraminol bitartrate with prednisolone 
sodium phosphate and dexamethasone sodium phosphate in Sodium 
Chloride Injection and 5% Dextrose Injection demonstrBted an 
altered absorption spectrum for the corticosteroid component. 
Prednisolone sodium phosphate exhibited a secondary Xmax 1 
whi fe dexamethasone sodium phosphate exhibited a wavelength 
~~~~~~~~~~~~~~~'---~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
shift in the Amax. 
The absorption spectrum for admixtures of metaraminol 
bitartr6i·e with hydrocortisone and hydrocortisone-21-phosphate 
In Sodium Chloride Injection and 5% Dextrose Injection was not 
significantly altered throughout the study.· 
Mixture of metaraminol bitartrate wlth the corticosteroids 
selected for Inclusion In this s1·udy produced solutions wiih 
pronounced acidity. The pH measurements for the ad~ixtures 
revealed that the acidity of the solutions was control ied, to 
a great extent, by the metaraminol bitartrate. Thfs assertion 
is made on the basis· that the resulting pH values were quite 
close to those observed when metaraminol Litartrate was added 
to the Infusion fluids, in the same concentrations, hut with-
out i·he addition of other drugs. Except in the cases of 
hydrocortisone and hydrocortlsone-21-phosph~ta, the pH change 
observed, with respect to the corticosteroid component, was 
associated with some alteration of the absorption spectrum. 
Providing that the spectrophotometrtc optimum concentra-
tion can be attained for each drug component of an intravenous 
99 
admixture, the results of this study suggest that differential 
spectrophotometric analysis offers a useful method of detect-
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